Bourgeon Capital Management LLC Takes Position in AbbVie Inc. $ABBV

Bourgeon Capital Management LLC bought a new position in shares of AbbVie Inc. (NYSE:ABBV) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 3,507 shares of the company’s stock, valued at approximately $801,000.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC raised its position in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC grew its position in shares of AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after buying an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. grew its position in shares of AbbVie by 5.0% during the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after buying an additional 789 shares in the last quarter. Loomis Sayles & Co. L P increased its stake in shares of AbbVie by 53.7% in the second quarter. Loomis Sayles & Co. L P now owns 53,995 shares of the company’s stock worth $10,023,000 after buying an additional 18,866 shares during the last quarter. Finally, River Road Asset Management LLC increased its stake in shares of AbbVie by 1.6% in the second quarter. River Road Asset Management LLC now owns 43,355 shares of the company’s stock worth $8,195,000 after buying an additional 674 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Price Performance

AbbVie stock opened at $217.39 on Wednesday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The company has a fifty day moving average price of $222.00 and a two-hundred day moving average price of $224.65. The company has a market cap of $384.38 billion, a PE ratio of 92.11, a P/E/G ratio of 0.74 and a beta of 0.34.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same period in the prior year, the company earned $2.16 earnings per share. The firm’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.2%. AbbVie’s dividend payout ratio is 293.22%.

Wall Street Analyst Weigh In

A number of research firms have commented on ABBV. Guggenheim reiterated a “buy” rating on shares of AbbVie in a research note on Thursday, March 12th. Barclays started coverage on shares of AbbVie in a research report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 target price for the company. Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. Piper Sandler increased their price target on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

Insider Transactions at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.08% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Earnings momentum and guidance: AbbVie posted a quarterly EPS beat and raised FY‑2026 guidance earlier this year, which supports investor confidence in near‑term earnings and cash flow (background company report).
• Positive Sentiment: Analyst support: BMO (via TipRanks coverage) maintained a Buy rating and $258 price target, reinforcing bullish sentiment among institutional investors. AbbVie: Immunology Strength, Strategic Acquisitions, and Patent Headwind Execution Support Buy Rating
• Positive Sentiment: Institutional buying: Beacon Investment Advisory increased its stake in ABBV, signaling continued institutional interest. Beacon Investment Advisory Services Inc. Has $19.86 Million Stock Position in AbbVie Inc. $ABBV
• Positive Sentiment: Aesthetics business activity: Allergan Aesthetics (an AbbVie unit) launched promotional CoolMonth offers and presented safety/efficacy data at AAD — both support the aesthetics revenue story. Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting® Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 AAD
• Positive Sentiment: Macro tax tailwind: Analysis shows corporate cash taxes fell materially under the new tax law, a factor that can boost free cash flow for large pharma including AbbVie. US Corporate Taxes Drop $65 Billion After Trump’s $3.4 Trillion Tax Law
• Neutral Sentiment: Stock commentary: MarketWatch notes ABBV rose but still slightly underperformed the broader market on the day; useful context for relative performance. AbbVie Inc. stock rises Tuesday, still underperforms market
• Neutral Sentiment: Upcoming event: AbbVie set its Q1 2026 earnings release and conference call for April 29 — an event that could drive volatility and provide fresh guidance. AbbVie to Host First-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Competitive messaging: AbbVie publicly defends Skyrizi’s efficacy edge as J&J launches Icotyde — shows competitive dynamics in immunology/dermatology but not an immediate structural change. As J&J Brings Icotyde to Market, AbbVie Remains Confident in Skyrizi’s Efficacy Edge
• Negative Sentiment: Oncology pressure: Analyst coverage (Zacks) highlights 2026 headwinds for AbbVie’s oncology revenue — Imbruvica pricing pressure may weigh on top‑line growth despite newer drug contributions. Will AbbVie’s Oncology Drugs Aid Top Line in 2026?
• Negative Sentiment: Lawsuit tied to Cerevel deal: A Bloomberg Law item says investors’ suit over the Cerevel deal involving Pfizer/Bain must proceed, which could raise legal risk/uncertainty around the transaction and reputational exposure. Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit
• Negative Sentiment: Peer M&A strengthens competition: Merck’s large oncology deal (Terns) reinforces competitive pressure in oncology — a potential headwind for AbbVie’s oncology growth narrative. Merck Just Made a Big Bet on a New Cancer Growth Engine

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.